Affymetrix (AFFX), ScreenCell Enter CTC Collection Buffer Distribution Agreement
Tweet
Share
E-mailGet Alerts AFFX Hot Sheet
Join SI Premium – FREE
Affymetrix, Inc. (Nasdaq: AFFX) and ScreenCell, signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.
The agreement makes Affymetrix the exclusive distributor of ScreenCell products used in combination with in situ hybridization (ISH) assays, microarray assays, and other non-PCR based nucleic acid assays including Affymetrix’ industry-leading QuantiGene ViewRNA Assays, QuantiGene Plex Assays, and GeneChip Microarray Assays.
The QuantiGene ViewRNA CTC platform, consist of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix.
The agreement makes Affymetrix the exclusive distributor of ScreenCell products used in combination with in situ hybridization (ISH) assays, microarray assays, and other non-PCR based nucleic acid assays including Affymetrix’ industry-leading QuantiGene ViewRNA Assays, QuantiGene Plex Assays, and GeneChip Microarray Assays.
The QuantiGene ViewRNA CTC platform, consist of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HCW Biologics advances two cancer drug candidates using TGF-β/IL-15
- Cincinnati Financial expands share buyback program by 15 million shares
- Cree LED and Nanolumens settle patent dispute with cross-license deal
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
